CIK 0001357874 · Non-accelerated filer<br>Smaller reporting company
PRECISION BIOSCIENCES INC
Sign in to watch- Ticker
- DTIL
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- May 21
- Incorporated
- DE
- Entity type
- operating
- Phone
- 919-314-5512
- Business address
- 302 EAST PETTIGREW STREET, SUITE A-100, DURHAM, NC, 27701
- Open-market buys, last 90 days
- $29,501
- in 3 filings
- Open-market sales, last 90 days
- $27,505
- in 1 filing, $28K under 10b5-1 plans
Net +$1,996. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-01-20 | Amoroso Michael President and CEO | Option exercise 10b5-1 | +115,388 | 143,925 | ||
| 2025-01-20 | Amoroso Michael President and CEO | Option exercise · Restricted Stock Units 10b5-1 | −8,888 | 8,888 | ||
| 2025-01-20 | Amoroso Michael President and CEO | Option exercise · Restricted Stock Units 10b5-1 | −37,079 | 74,138 | ||
| 2025-01-20 | Amoroso Michael President and CEO | Option exercise · Restricted Stock Units 10b5-1 | −69,421 | 138,842 | ||
| 2025-01-20 | Kelly John Alexander Chief Financial Officer | Option exercise | +44,368 | 84,554 | ||
| 2025-01-20 | Kelly John Alexander Chief Financial Officer | Option exercise · Restricted Stock Units | −3,889 | 3,888 | ||
| 2025-01-20 | Kelly John Alexander Chief Financial Officer | Option exercise · Restricted Stock Units | −13,904 | 27,801 | ||
| 2025-01-20 | Kelly John Alexander Chief Financial Officer | Option exercise · Restricted Stock Units | −26,575 | 53,150 | ||
| 2025-01-20 | SMITH J. JEFFERSON Chief Research Officer | Option exercise 10b5-1 | +29,168 | 97,727 | ||
| 2025-01-20 | SMITH J. JEFFERSON Chief Research Officer | Option exercise · Restricted Stock Units 10b5-1 | −2,500 | 2,500 | ||
| 2025-01-20 | SMITH J. JEFFERSON Chief Research Officer | Option exercise · Restricted Stock Units 10b5-1 | −10,449 | 20,894 | ||
| 2025-01-20 | SMITH J. JEFFERSON Chief Research Officer | Option exercise · Restricted Stock Units 10b5-1 | −16,219 | 32,438 | ||
| 2024-12-30 | Germano Geno J Director | Purchase | +3,605 | $4.49 | $16K | 7,807 |
| 2024-12-27 | Buehler Kevin Director | Purchase | +4,320 | $4.88 | $21K | 8,712 |
| 2024-12-27 | Kelly John Alexander Chief Financial Officer | Purchase | +2,113 | $4.75 | $10K | 40,186 |
| 2024-12-26 | Brown Melinda Director | Purchase | +3,016 | $4.55 | $14K | 7,218 |
| 2024-11-21 | Kelly John Alexander Chief Financial Officer | Purchase | +3,000 | $6.76 | $20K | 38,073 |
| 2024-11-04 | Scimeca Dario General Counsel and Secretary | Sale 10b5-1 | −588 | $8.19 | $5K | 7,969 |
| 2024-11-04 | Amoroso Michael President and CEO | Sale | −3,012 | $8.19 | $25K | 28,537 |
| 2024-11-02 | Kelly John Alexander Chief Financial Officer | Option exercise | +3,605 | 35,073 |
Page 7 of 11 · 210 trades